| INTRODUCTION
China carries the highest diabetes burden of any country worldwide, 1 with an estimated prevalence of 10.9% in 2013. 2 Consistent with observations in Western populations, diabetes is a major risk factor for developing cardiovascular disease (CVD) in Chinese adults. 3 Furthermore, as is the case globally, Chinese patients with type 2 diabetes mellitus (T2DM) have an increased risk of cardiovascular events, including cardiovascular death, myocardial infarction, hypertension and stroke. [4] [5] [6] [7] Low-density lipoprotein cholesterol (LDL-C) is the primary target in the treatment of dyslipidaemia in patients with T2DM, [8] [9] [10] [11] as elevated LDL-C has been associated with increased risk of CVD and cardiovascular events. [12] [13] [14] Chinese guidelines for the treatment of dyslipidaemia in high-risk patients with T2DM recommend statinbased therapy for maintaining LDL-C below 1.8 mmol/L. 11 Despite the availability of statin therapy in China and Southeast Asia, attainment of recommended LDL-C levels has been suboptimal, with 60%
to 72% of patients with T2DM in community clinics or hospitals failing to achieve recommended LDL-C levels. [15] [16] [17] [18] Observational, pharmacological and pharmacogenetic studies suggest that statin-related adverse reactions occur at higher rates among Chinese patients than would be observed in a global population. 19 Suboptimal reduction in LDL-C among Chinese patients may, therefore, be driven by intolerance to high-potency high-dose statin treatment, and under-utilization may be driven by statin-related adverse reactions. 19, 20 Consequently, there is an urgent unmet need for novel lipid-lowering therapies for addition to the maximally-tolerated statin dose in China.
Analyses from phase 2 and 3 clinical trials have consistently shown that evolocumab, a human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduces LDL-C without adversely affecting objective measures of glycaemic control in patients with or without diabetes. [21] [22] [23] [24] [25] In the global, randomized, double-blind, 12-week phase 3 BERSON study (N = 986), in which approximately half of the patients with T2DM and hyperlipidaemia or mixed dyslipidaemia were enrolled from Chinese centres, efficacy results from the global population showed that evolocumab significantly reduced LDL-C and improved other lipid levels compared with placebo when administered in combination with background atorvastatin. 26, 27 In the global population, evolocumab was safe and well tolerated, with no notable changes in glycaemic measures throughout the study. This prespecified analysis of the BERSON study was designed to investigate the efficacy and safety of evolocumab combined with background atorvastatin in patients at Chinese centres. at screening were obliged to have LDL-C of at least 3.4 mmol/L (≥130 mg/dL). It was required that the lipid-lowering therapy status of patients remained unchanged for at least four weeks before LDL-C screening. The study design and rationale, as well as full inclusion and exclusion criteria, were described previously. 26, 27 This prespecified analysis includes only patients who were randomized at centres in China. The study was conducted in accordance with the Guidelines on Good Clinical Practice and with the Ethical Standards for Human Experimentation established by the Declaration of Helsinki. An independent review board or independent ethics committee at each study site reviewed the study and approved the protocol and subsequent amendments to the study protocol. An external, independent data monitoring committee (DMC) periodically reviewed study data, and analyses for the DMC were provided by an independent biostatistical group. All patients provided informed consent before participation.
Because most Chinese patients cannot tolerate the high-intensity statin treatment recommended by the ACC/AHA, 8 atorvastatin 20 mg once daily (QD) was selected, based on Chinese dyslipidaemia guidelines and the expected LDL-C response in Chinese patients. [28] [29] [30] More recent guidelines in China are consistent with this approach.
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At screening and at each subsequent visit, patients were instructed to maintain their diet, as well as any allowed therapy and exercise regimen. The last dose of evolocumab or placebo was given at week 8 for QM patients and at week 10 for Q2W patients. The final study visit was at week 12 for QM patients and a phone visit at week 14 for Q2W patients. Baseline covariates for subgroup analysis of coprimary efficacy endpoints included statin therapy at study entry (yes vs no), age, sex, race, baseline LDL-C, family history of premature coronary heart disease, baseline PCSK9, body mass index, hypertension, status as current smoker, ≥2 baseline CHD risk factors and triglycerides. Treatment assignment was blinded to the sponsor's study team, investigators, site staff and patients throughout the study and remained blinded until unblinding of the clinical database.
| Study assessments
As in the global population, blood assessments of patients enrolled at centres in China included fasting levels of lipids (total cholesterol, LDL-C, triglycerides, VLDL-C, non-HDL-C and HDL-c) at screening, at This pre-specified analysis presents study results for all randomized patients enrolled at Chinese centres who received at least one one dose of study drug, that is, the China full analysis set (CFAS). The efficacy of evolocumab compared with placebo in the CFAS concerning the co-primary endpoints (percentage change from baseline in LDL-C at week 12 and the mean of weeks 10 and 12) and the continuous co-secondary endpoints was compared using repeated-measures linear mixed-effects models with terms for treatment group, a stratification factor (statin therapy at study entry [yes vs no]), scheduled visit and interaction of treatment with the scheduled visit. In the CFAS, each independent dose frequency (Q2W and QM) was allocated a significance level of 0.025 for the co-primary endpoints. 33 LDL-C target achievement was assessed using the Cochran-Mantel-Haenszel test, adjusted by existence of statin therapy at study entry (yes vs no).
Safety assessments were summarized descriptively. As part of the China analyses, a subgroup analysis of co-primary endpoints was also performed for Chinese vs non-Chinese patients in FAS. Baseline characteristics for subgroup analysis of co-primary efficacy endpoints included existence of statin therapy at study entry, age, sex, baseline LDL-C, baseline PCSK9 level, body mass index, hypertension, current smoking status, baseline coronary heart disease risk factors and baseline triglycerides.
3 | RESULTS
| Patients
The study was conducted from 14 April 2016 through 6 December 2017. The global study population is described by Lorenzatti et al. 26, 27 Overall, 1261 patients were screened at centres in China, of whom Mean baseline lipid values (SD) Abbreviations: ACC/AHA, American College of Cardiology/American Heart Association; ApoB100, apolipoprotein B100; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); SD, standard deviation; VLDL-C, very low-density lipoprotein cholesterol.
a Patient had at least one of the following recorded for the last four weeks before screening: atorvastatin ≥40 mg QD; rosuvastatin ≥20 mg QD; simvastatin ≥80 mg QD (simvastatin 80 mg QD is not approved in some countries, eg, USA); and any statin (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin) QD plus ezetimibe. b Patient has been taking any dose of a statin at least weekly for the last four weeks before screening and was not included in the intensive statin usage. −75.6; P < 0.0001) with QM dosing at the mean of weeks 10 and 12 ( Table 2) . At week 12, the least-squares mean absolute change The treatment effect on LDL-C, by scheduled visits and treatment groups for Q2W and QM regimens, is shown in Figure 2 . LDL-C concentrations were reduced to below 70 mg/dL (1.8 mmol/L) in 96.4%
and 95.1% of patients in the evolocumab Q2W and QM groups, respectively, at week 12 and in 97.2% and 95.3% of patients in the evolocumab Q2W and QM groups, respectively, at the mean of weeks 10 and 12 ( Table 2 ). Subgroup analyses of co-primary endpoints demonstrated consistency of the effect of evolocumab treatment across all subgroups among Chinese patients ( Figure S1 ). Trough evolocumab concentrations were comparable at weeks 8, 10 and 12 following administration of evolocumab 140 mg Q2W, and were comparable at weeks 8 and 12 in the evolocumab 420 mg QM treatment group (Table S1 ).
Changes from baseline in secondary lipid parameters are summarized in Table 2 analysis, qualitative interaction testing demonstrated common directionality of the LDL-C lowering effect and non-significant P-values.
| Safety
Among patients enrolled at Chinese centres, the incidence of AEs was greater in the overall evolocumab group than in the overall placebo group (57.6% vs 53.0%) ( 
| DISCUSSION
To our knowledge, the BERSON study is the first dedicated T2DM study involving a PCSK9 inhibitor that enrolled patients in China. In F I G U R E 2 Mean percentage change in LDL-C from baseline to scheduled visits in LDL-C for Q2W dosing (A) and QM dosing (B). Vertical lines represent standard error around the mean. No imputation was used for missing values. When the calculated LDL-C was <1.0 mmol/L or triglycerides were > 4.5 mmol/L, calculated LDL-C was replaced with ultracentrifugation LDL-C from the same blood sample, if available at Chinese centres had significant reductions in LDL-C, by 75% to 85%, and in non-HDL-C, by 63% to 81%. Significant improvements in other atherogenic lipid parameters were also observed after 12 weeks of treatment with evolocumab. Furthermore, more than 90% of the Chinese patients who received evolocumab with background atorvastatin of moderate intensity were able to achieve LDL-C values below 1.8 mmol/L (95%-97% with evolocumab vs 24%-25% with placebo).
These results are noteworthy, considering that, in previous studies in Chinese and Southeast Asian community hospitals or clinics, the majority of patients with diabetes and CVD risk factors who received statins or other lipid-lowering therapies did not attain recommended levels of LDL-C. [15] [16] [17] [18] While subgroup analysis of co-primary endpoints showed statistically significant differences in the magnitude of LDL-C reduction between Chinese and non-Chinese populations, treatment effects are directionally consistent, favouring evolocumab, in the two subgroups. Least-squares mean Lp(a) reduction with evolocumab, a co-secondary efficacy endpoint, was also greater in
Chinese patients compared with the global population. These findings could not be explained by differences in adherence to the investigational product or to other lipid-lowering therapies, by LDL levels in the placebo groups or by differences in evolocumab pharmacokinetic exposure or serum PCSK9 levels; thus, further investigation may be warranted. Observations in the Chinese population are consistent with results reported in Japanese patients treated with evolocumab over 12 weeks, with least-squares mean LDL-C reductions ranging from 67% to 76%, compared with placebo, when combined with atorvastatin 20 mg daily, and LDL-C less than 1.8 mmol/L was achieved by 96% to 98% of patients. 34 The substantial reductions in LDL-C with evolocumab vs placebo among Chinese patients in the BERSON study are consistent with those observed in prior evolocumab global studies in patients with hypercholesterolaemia or mixed dyslipidaemia, 35 in patients with T2DM, 36 and in a meta-analysis and pooled analysis of data from 12-week phase 3 studies. 24, 37 Prior analyses showed that the LDL-C treatment effect with evolocumab is maintained over time in patients with and without diabetes. 21, 23 Our results are also consistent with those from a systematic review including 20 randomized controlled studies with PCSK9 inhibitors (alirocumab, bococizumab and evolocumab). 38 The ODYSSEY KT study, which assessed the efficacy and safety of the PCSK9 inhibitor alirocumab in 199 patients at high cardiovascular risk enrolled in South Korea and Taiwan, also showed statistically significant reductions in LDL-C. 39 Patient was assigned to QM dosing, reported at week 8 visit, remained asymptomatic, and returned to baseline at week 12.
